Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 5/20 | 0.53 |
| ▸ | AXL | P30530 | 7/20 | 0.53 |
| ▸ | CDK8 | P49336 | 3/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.53 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796715 | 0.88 | AXL (0.61) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL15500884 | 0.83 | AXL (0.54) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL15500801 | 0.82 | AXL (0.59) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL1800577 | 0.81 | MAP3K11 (0.55) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL1799165 | 0.81 | AXL (0.49) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL15500880 | 0.80 | SGK1 (0.57) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL1799005 | 0.80 | AXL (0.63) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL15500885 | 0.80 | MAP3K11 (0.57) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL15500802 | 0.79 | CDK8 (0.64) | SGK1AXLCDK8TNIKCAMKK2 | |
| SCHEMBL1801878 | 0.79 | HTR2C (0.56) | SGK1AXLCDK8TNIKCAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765819-B1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | SGK1 94/4885AXL 4101/4885CDK8 500/4885 |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | SGK1 113/4885AXL 4302/4885CDK8 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.